BNP Paribas Financial Markets Increases Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

BNP Paribas Financial Markets grew its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 208.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,512 shares of the company’s stock after purchasing an additional 1,698 shares during the period. BNP Paribas Financial Markets’ holdings in Jasper Therapeutics were worth $47,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. American Century Companies Inc. increased its stake in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new position in shares of Jasper Therapeutics in the third quarter worth $59,000. Fernwood Investment Management LLC grew its stake in shares of Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after acquiring an additional 3,427 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics during the second quarter worth $300,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at $329,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on JSPR. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Thursday, October 24th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective on the stock. Finally, Evercore ISI restated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Buy” and a consensus price target of $73.38.

Jasper Therapeutics Trading Up 2.5 %

Shares of Jasper Therapeutics stock opened at $21.53 on Friday. The company has a fifty day simple moving average of $21.36 and a 200-day simple moving average of $20.78. Jasper Therapeutics, Inc. has a 12-month low of $5.00 and a 12-month high of $31.01. The stock has a market cap of $322.97 million, a price-to-earnings ratio of -4.54 and a beta of 2.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.